Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sunshine Lake Pharma and Xtalpi Form AI Drug Discovery Joint Venture

Fineline Cube Jan 27, 2026
Company Deals

HanchorBio Partners with WuXi Biologics on Next‑Gen Fusion Protein Manufacturing

Fineline Cube Jan 27, 2026
Company Deals

Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform

Fineline Cube Jan 26, 2026
Company Deals

GenEditBio Partners with uBriGene on LNP Ex Vivo Tech for Cell Therapy Manufacturing

Fineline Cube Jan 26, 2026
Company Deals

Merck Abandons $32 Billion Revolution Medicines Acquisition Over Price Dispute

Fineline Cube Jan 26, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency

Fineline Cube Jan 27, 2026
Company Drug

Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30

Fineline Cube Jan 26, 2026
Company Deals

Beijing Huashen Shengdian Secures Angel Funding for Pelvic Surgery Monitor R&D

Fineline Cube Feb 21, 2023

China-based intraoperative nerve monitoring technology developer Beijing Huashen Shengdian Medical Technology Co., Ltd has reportedly...

Company Drug

Zhaoke’s Generic Bimatoprost + Timolol Maleate Eye Drops Approved in China

Fineline Cube Feb 21, 2023

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) former subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) has announced...

Company Drug

Sino Biopharmaceutical’s Limaprost Approved by NMPA for Lumbar Spinal Stenosis Treatment

Fineline Cube Feb 21, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received marketing approval from China’s...

Company R&D

Biocytogen’s ‘Nano 100 Project’ Aims to Develop Over 100 Fully Human Nanobody Drugs

Fineline Cube Feb 21, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced the launch of the “Nano 100 Project,”...

Company Deals

Suzhou Porton Biologics Partners with Yinjia Biosciences for CGT Development

Fineline Cube Feb 21, 2023

China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has struck a partnership...

Company Drug

Biosyngen’s BRG01 Gets FDA Nod for NPC Clinical Study

Fineline Cube Feb 20, 2023

Cell and gene therapy (CGT) specialist Biosyngen Pte Ltd has announced receiving approval from the...

Policy / Regulatory

CDE Issues Guidelines for Real-World Drug Research and Evidence Framework

Fineline Cube Feb 20, 2023

The Center for Drug Evaluation (CDE) has released two important documents: the “Guiding Principles of...

Company Policy / Regulatory

China’s 8th Volume-Based Procurement Round Begins Drug Info Filing

Fineline Cube Feb 20, 2023

The national drug alliance procurement office has released a notification initiating the drug information filing...

Company Drug

BRL Medicine Achieves First Cure of Thalassemia Major with BRL-101

Fineline Cube Feb 20, 2023

Shanghai-based BRL Medicine Inc. has announced a significant breakthrough in the treatment of thalassemia major....

Company Drug

Immuno Cure BioTech Launches Phase I HIV/AIDS Vaccine Study

Fineline Cube Feb 20, 2023

China-based Immuno Cure BioTech has announced the initiation of a Phase I clinical study for...

Company Deals

Clover Biopharmaceuticals Secures Exclusive Deal for AdimFlu-S Distribution in China

Fineline Cube Feb 20, 2023

China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced an exclusive agreement with Adimmune Corporation for...

Company Deals

Hainan Honz Partners with GPI for Pediatric and Maternity Medicine Expansion

Fineline Cube Feb 20, 2023

China-based Hainan Honz Pharmaceutical Co., Ltd (SHE: 300086) has entered into a three-year partnership with...

Company Deals R&D

MoleculeMind Raises Over RMB 100 Million for AI Protein Design Platform

Fineline Cube Feb 20, 2023

MoleculeMind, an artificial intelligence (AI)-empowered protein design platform based in Beijing, has reportedly raised over...

Drug Policy / Regulatory

Zhejiang Suspends Generic Nesina Trading Due to IP Disputes

Fineline Cube Feb 20, 2023

Zhejiang’s Provincial Center for Drug & Medical Device Procurement has issued a notification suspending the...

Policy / Regulatory

China’s 2022 Western Medicine Trade Analysis: Growth and Challenges

Fineline Cube Feb 20, 2023

The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...

Company Drug

Wuhan Binhui’s Oncolytic Virus Therapy Awarded Breakthrough Designation by CDE

Fineline Cube Feb 20, 2023

The Center for Drug Evaluation (CDE) website indicates that China-based Wuhan Binhui Biotechnology Co., Ltd’s...

Company Drug

CDE Awards Priority Review to Eisai’s Lecanemab for Early Alzheimer’s Disease

Fineline Cube Feb 20, 2023

The Center for Drug Evaluation (CDE) website indicates that Japan-based Eisai’s (TYO: 4523) lecanemab has...

Company Deals Medical Device

Chunlizhengda to Acquire Majority Stake in Surgimaster for Medical Power Tools

Fineline Cube Feb 20, 2023

Beijing Chunlizhengda Medical Instruments Co., Ltd (HKG: 1858, SHA: 688236) is poised to acquire a...

Company Deals

Duoning Biotech Secures Global Rights to Junzhen’s Cell Counter Products

Fineline Cube Feb 20, 2023

China’s Shanghai Duoning Biotechnology Co., Ltd has entered into a licensing deal with compatriot firm...

Company Deals

Sansure Biotech Partners with Hunan Normal University for Research and Talent Development

Fineline Cube Feb 18, 2023

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has announced a strategic partnership with...

Posts pagination

1 … 509 510 511 … 614

Recent updates

  • Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency
  • Sunshine Lake Pharma and Xtalpi Form AI Drug Discovery Joint Venture
  • HanchorBio Partners with WuXi Biologics on Next‑Gen Fusion Protein Manufacturing
  • Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30
  • Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency

Company Deals

Sunshine Lake Pharma and Xtalpi Form AI Drug Discovery Joint Venture

Company Deals

HanchorBio Partners with WuXi Biologics on Next‑Gen Fusion Protein Manufacturing

Company Drug

Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.